77 results on '"Hunger, Stephen P"'
Search Results
2. Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia
3. Sex‐based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report
4. SIOP Strategy 2021–2025: Cure for more, care for all
5. Late isolated central nervous system relapse in childhood B‐cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2
6. Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity
7. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group
8. How we approach Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and young adults
9. Delayed cancer diagnoses and high mortality in children during the COVID‐19 pandemic
10. The ASPHO 2020 distinguished career award goes to Dr Garrett M. Brodeur
11. Epigenetic silencing of SOCS5 potentiates JAK‐STAT signaling and progression of T‐cell acute lymphoblastic leukemia
12. Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group
13. No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy
14. The ASPHO 2018 Distinguished Career Award goes to Dr. Michael P. Link
15. Isolated late testicular relapse of B‐cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response‐based testicular radiation: A Children's Oncology Group study
16. Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232
17. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131
18. A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP)
19. Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial
20. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylatedErwiniaasparaginase, pegcrisantaspase: A report from the Children's Oncology Group
21. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics
22. Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia
23. Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study
24. Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma
25. Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group
26. Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia-Comparison among Different Treatment Strategies
27. Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331
28. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy
29. SVSI: Fast and Powerful Set-Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits
30. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434
31. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2
32. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group
33. Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)
34. Clinical application of asparaginase activity levels following treatment with pegaspargase
35. Family life events in the first year of acute lymphoblastic leukemia therapy: A children's oncology group report
36. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia
37. Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia
38. A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia
39. Predicting relapse risk in childhood acute lymphoblastic leukaemia
40. Children are not large mice
41. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7–9, 2011
42. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ALL: a Children's Oncology Group (COG) study
43. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906
44. Improving outcomes for high‐risk ALL: Translating new discoveries into clinical care
45. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy
46. L-asparaginase treatment in acute lymphoblastic leukemia
47. Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A
48. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference
49. Native kidney post-transplant lymphoproliferative disorder in a non-renal transplant patient
50. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low‐income countries: A proposal
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.